

# Brent Butts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4413657/publications.pdf>

Version: 2024-02-01

10  
papers

680  
citations

1163117

8  
h-index

1474206

9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1181  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glycogen Synthase Kinase-3 $\beta$ Phosphorylates Bax and Promotes Its Mitochondrial Localization during Neuronal Apoptosis. <i>Journal of Neuroscience</i> , 2004, 24, 9993-10002.	3.6	340
2	Maturation-dependent sensitivity of oligodendrocyte lineage cells to apoptosis: implications for normal development and disease. <i>Cell Death and Differentiation</i> , 2008, 15, 1178-1186.	11.2	101
3	The permeability transition pore triggers Bax translocation to mitochondria during neuronal apoptosis. <i>Cell Death and Differentiation</i> , 2005, 12, 255-265.	11.2	77
4	Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression. <i>Cancer Letters</i> , 2001, 173, 115-125.	7.2	68
5	Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors. <i>Molecular and Cellular Neurosciences</i> , 2005, 30, 279-289.	2.2	36
6	Distinct mechanisms of neuronal apoptosis are triggered by antagonism of Bcl-2/Bcl-x(L) versus induction of the BH3-only protein Bim. <i>Journal of Neurochemistry</i> , 2005, 94, 22-36.	3.9	23
7	Generation and characterization of antibodies specific for caspase-cleaved neo-epitopes: a novel approach. <i>Cell Death and Disease</i> , 2011, 2, e205-e205.	6.3	17
8	MerCASBA: an updated and refined database of caspase substrates. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 369-371.	4.9	12
9	Identification of a functional peroxisome proliferator activated receptor response element in the 3' untranslated region of the human bcl-2 gene. <i>International Journal of Oncology</i> , 2004, 24, 1305.	3.3	6
10	Phase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii135.	1.2	0